April 25, 2019
Boehringer Ingelheim Japan said on April 24 that its ethical drug sales in 2018 tumbled 18.4% over the previous year to 189.3 billion yen on an NHI price basis in the face of a generic onslaught hitting its Micardis (telmisartan)...read more